Format

Send to

Choose Destination
Cancer. 2016 May 15;122(10):1588-97. doi: 10.1002/cncr.29951. Epub 2016 Mar 11.

Patient preferences regarding incidental genomic findings discovered during tumor profiling.

Author information

1
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
2
Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

Abstract

BACKGROUND:

During the process of tumor profiling, there is the potential to detect germline variants. To the authors' knowledge, there currently is no accepted standard of care for how to deal with these incidental findings. The goal of the current study was to assess disclosure preferences among patients with cancer regarding incidental genomic variants that may be discovered during tumor profiling.

METHODS:

A 45-item questionnaire was administered to 413 patients in ambulatory oncology clinics. The survey captured demographic and disease variables and personal and family history, and presented case scenarios for different types of incidental germline variants that could theoretically be detected during genomic analysis of a patient's tumor.

RESULTS:

The possibility of discovering non-cancer-related, germline variants did not deter patients from tumor profiling: 77% wanted to be informed concerning variants that could increase their risk of a serious but preventable illness, 56% wanted to know about variants that cause a serious but unpreventable illness, and 49% wanted to know about variants of uncertain significance. The majority of patients (75%) indicated they would share hereditary information regarding predisposition to preventable diseases with family and 62% would share information concerning unpreventable diseases. The most frequent concerns about incidental findings were ability to obtain health (48%) or life (41%) insurance. Only 21% of patients were concerned about privacy of information.

CONCLUSIONS:

Patients with cancer appear to prefer to receive information regarding incidental germline variants, but there is substantial variability with regard to what information patients wish to learn. The authors recommend that personal preferences for the disclosure of different types of incidental findings be clarified before a tumor profiling test is ordered. Cancer 2016;122:1588-97. © 2016 American Cancer Society.

KEYWORDS:

disclosure; genome; genomics; germline mutation; incidental findings; questionnaire

PMID:
26970385
DOI:
10.1002/cncr.29951
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center